Skip to content

Clinical trial of hair vitamin gummies to improve hair and nail health

A Randomized double-blind placebo-controlled clinical trial to evaluate the safety and efficacy of hair vitamin gummies in reducing hair fall and improving hair and nail health in adults - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050199
Enrollment
60
Registered
2023-03-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

Interventions

Intervention1: Hair Vitamin gummies: 1 gummy per day after breakfast for the treatment group for 90 days. Control Intervention1: Placebo Gummy: 1 gummy per day after breakfast for placebo group for 90

Sponsors

Mosaic Wellness Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male and female subjects in general good health; 2.Subjects in the age group of 18-35 years (both inclusive); 3.Subjects willing to give a written informed consent and agree to come for a regular follow up visit; 4. Female subjects falling under Grade roman number one-1 to roman number two-1 of Savins pictorial grading of female pattern hair loss or male subjects falling under Grade two to four A of hair loss severity grade evaluated as per Norwood scale; 5.Subject with at least one of the following complaints- •Dry damaged hair •Brittle and thin hair •Hair loss evident while combing or after washing •Perceived reduced hair density •Scalp related complaints like itching, dandruff or irritation.

Exclusion criteria

Exclusion criteria: 1.Subjects who are undergoing hair growth treatment within 3 months before screening into the study; 2.Subjects having any active scalp disease which may interfere in the study; 3.Subjects on treatment for active acne; 4.Subjects with history or active phase of malignancy and chemotherapy; 5.Subjects who have history of alcoholism and/ or psychiatric disorder including trichotillomania; 6.Subjects who have had hair transplant; 7.Subjects who take pharmaceutical product which cause hirsutism; 8.Subjects on oral hair growth medications which will compromise the study; 9.Chronic illness which may influence the study; 10.Subjects participating in other similar cosmetic or therapeutic trial within last two weeks; 11.Pregnant or lactating mothers; 12.Any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension (›140/90 mmHg), HIV, hepatitis, severe anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness; 13.Any other condition, as per the discretion of the investigator, that can impact the study outcome or subjects will not be considered in the study.

Design outcomes

Primary

MeasureTime frame
1.Change in the hair density in the target area by phototrichogram at screening visit and end of the study. 2.Change in hair growth rate from screening visit to end of the study. 3.Change in anagen to telogen ratio (A/T ratio) at screening visit and end of the study.Timepoint: Screening, day 30, day 60 and day 90

Secondary

MeasureTime frame
1.Change in the number of terminal hairs, vellus hairs and hair diameter in the target area by phototrichogram at screening visit and end of the study. 2.Change in the number of shredded hairs after “60 Second Hair Comb test ? from screening to end of the study. 3.Change in the number of shredded hairs after “Modified hair wash test ? from screening to end of the study. 4.Change in nail growth rate assessed by dermatologist from screening visit to end of the study. 5.Change in self-assessment questionnaire score for hair and nail at screening and end of the study. 6.Change in visual analog scale (VAS) score for scalp related complaints like itching, dandruff or irritation reported by subjects from screening to end of the study.Timepoint: Screening, day 30, day 60 and day 90

Countries

India

Contacts

Public ContactAbhinav Gupta

Mosaic Wellness Pvt. Ltd.

abhishek.kanade@mosaicwellness.in9029243493

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026